[1]龚殿炳.芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭的临床效果及对心室重构的影响[J].医学信息,2023,36(23):99-102.[doi:10.3969/j.issn.1006-1959.2023.23.025]
　GONG Dian-bing.Clinical Effect of Qili Qiangxin Capsules Combined with Sacubitril Valsartan in Treatment of Chronic Heart Failure and its Effect on Ventricular Remodeling[J].Journal of Medical Information,2023,36(23):99-102.[doi:10.3969/j.issn.1006-1959.2023.23.025]
点击复制

芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭的临床效果及对心室重构的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年23期
页码:
99-102
栏目:
论著
出版日期:
2023-12-01

文章信息/Info

Title:
Clinical Effect of Qili Qiangxin Capsules Combined with Sacubitril Valsartan in Treatment of Chronic Heart Failure and its Effect on Ventricular Remodeling
文章编号:
1006-1959（2023）23-0099-04
作者:
龚殿炳
（万安县人民医院内二科，江西 万安 343800）
Author(s):
GONG Dian-bing
(The Second Department of Internal Medicine,Wan’an County People’s Hospital,Wan’an 343800,Jiangxi,China)
关键词:
芪苈强心胶囊; 沙库巴曲缬沙坦; 慢性心力衰竭; 心室重构
Keywords:
Qili Qiangxin capsule; Sacubitril valsartan; Chronic heart failure; Ventricular remodeling
分类号:
R541
DOI:
10.3969/j.issn.1006-1959.2023.23.025
文献标志码:
A
摘要:
目的 研究芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭临床效果及对心室重构的影响。方法 选取2020年1月-2022年9月我院诊治的60例慢性心力衰竭患者为研究对象，采用随机数字表法分为对照组和观察组，各组30例。对照组采用沙库巴曲缬沙坦治疗，观察组在对照组基础上联合应用芪苈强心胶囊治疗，比较两组治疗效果、心功能指标[心率、左心室射血分数（LVEF）、左心室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）]、N末端脑利钠肽前体（NT－proBNP）、C反应蛋白（CRP）、不良反应发生率。结果 观察组治疗总有效率为93.33%，高于对照组的80.00%（P＜0.05）；两组治疗后心率、LVEDD、LVESD低于治疗前，LVEF高于治疗前，且观察组心率、LVEDD、LVESD低于对照组，LVEF高于对照组（P＜0.05）；两组治疗后NT-proBNP、CRP水平低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭的临床效果理想，可改善心功能指标，延缓心室重构，且不增加不良反应发生几率，是一种安全、有效的治疗方案。
Abstract:
Objective To study the clinical effect of Qili Qiangxin capsules combined with sacubitril valsartan in treatment of chronic heart failure and its effect on ventricular remodeling.Methods A total of 60 patients with chronic heart failure diagnosed and treated in our hospital from January 2020 to September 2022 were selected as the research objects. They were divided into control group and observation group by random number table method, with 30 patients in each group. The control group was treated with sacubitril valsartan, and the observation group was treated with Qili Qiangxin capsule on the basis of the control group. The therapeutic effect, cardiac function indexes [heart rate, left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD)], N-terminal pro-brain natriuretic peptide (NT-proBNP), C-reactive protein (CRP), and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.33%, which was higher than 80.00% in the control group (P<0.05). After treatment, the heart rate, LVEDD and LVESD of the two groups were lower than those before treatment, LVEF was higher than that before treatment, and the heart rate, LVEDD and LVESD of the observation group were lower than those of the control group, LVEF was higher than that of the control group (P<0.05). After treatment, the levels of NT-proBNP and CRP in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion Qili Qiangxin capsule combined with sacubitril valsartan has an ideal clinical effect in the treatment of chronic heart failure, which can improve cardiac function indexes, delay ventricular remodeling, and does not increase the incidence of adverse reactions, so it is a safe and effective treatment plan.

参考文献/References:

[1]陈溢琳,王东江,王春颖.卡维地洛联合缬沙坦对慢性心力衰竭患者的疗效[J].心血管康复医学杂志,2016,25(2):158-161.[2]张钿,金钊,白晓军.缬沙坦对慢性心力衰竭患者心功能、心室重构及基质金属蛋白酶的影响[J].中国心血管病研究,2017,15(8):744-747.[3]黄小平,郑德进,王高生.缬沙坦治疗高血压伴心力衰竭的疗效 及其对患者血清hs-CRP水平、生活质量的影响[J].海南医学,2018,29(14):2033-2035.[4]胡勇钧,唐哨勇,陈姣,等.缬沙坦或贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床研究[J].中国临床药理学杂志,2016,32(4):291-293.[5]肖京,郭增玉.不同剂量诺欣妥治疗慢性心力衰竭伴慢性肾功能不全对患者血清sST2、CysC水平的影响[J].武警后勤学院学报(医学版),2021,30(6):34-38.[6]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.[7]董萌.沙库巴曲缬沙坦钠治疗老年慢性心力衰竭合并肾功能不全患者的临床观察[J].中国中西医结合急救杂志,2020,27(1):84-87.[8]陈宗伟,沈志涛,郑振国,等.芪苈强心胶囊配合保元汤加减治疗慢性心力衰竭临床研究[J].陕西中医,2020,41(2):191-193.[9]王斌.芪苈强心胶囊联合心脏康复运动对慢性心力衰竭患者心功能和心室重构的影响[J].心脑血管病防治,2018,18(6):506-508.[10]胡霜,蔡莉,张川平.美托洛尔联合芪苈强心胶囊治疗慢性心力衰竭的疗效观察[J].重庆医学,2017,46(5):689-691.[11]董小伟,王红雷,来利红,等.沙库巴曲缬沙坦联合比索洛尔治疗慢性心力衰竭的临床研究[J].现代药物与临床,2018,33(11):2791-2794.[12]Garganeeva AA,Kuzheleva EA,Kuzmichkina MA,et al.Characteristics and treatment of patients with heart failure admitted to a cardiology department in 2002 and 2016[J].Kardiologiia,2018,58(12S):18-26.[13]高巧燕,王明蕾.芪苈强心胶囊治疗慢性心力衰竭的疗效观察[J].中国医院用药评价与分析,2017,17(9):1186-1187,1190.[14]孟海娜,谢嘉怡,何微.托伐普坦治疗慢性心力衰竭合并低钠血症的效果[J].中国医科大学学报,2019,48(6):551-554.[15]余福东.芪苈强心胶囊对慢性心力衰竭患者脑利钠肽及抗利尿激素水平的影响[J].中国药业,2016,25(12):61-63.[16]段雯.温心逐水化瘀汤加减联合芪苈强心胶囊治疗慢性充血性心力衰竭[J].河南医学研究,2019,28(19):3580-3581.[17]殷国田,解娜,黄艳梅,等.芪苈强心胶囊联合辅酶Q10对老年高血压并心衰患者心肌营养素-1、丙二醛水平的影响[J].中国老年学杂志,2017,37(9):2149-2151.[18]罗平,万凤福.芪苈强心胶囊联合西药治疗射血分数保留的心衰临床观察[J].江西医药,2016,51(10):1069-1071.[19]苏成标,许锦荣,陈庞何,等.芪苈强心胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭的临床疗效及其对血清基质裂解素2水平的影响[J].广东医科大学学报,2020,38(1):37-40.[20]王慧莹,许涛,张海平.沙库巴曲缬沙坦钠片联合芪苈强心胶囊在慢性心力衰竭治疗中的应用[J].河北北方学院学报(自然科学版),2021,37(4):42-43,46.

相似文献/References:

[1]李 龙,汪莲开.沙库巴曲缬沙坦在心力衰竭治疗中的应用[J].医学信息,2020,33(02):58.[doi:10.3969/j.issn.1006-1959.2020.02.016]
　LI Long,WANG Lian-kai.Application of Shakubatrivasartan in the Treatment of Heart Failure[J].Journal of Medical Information,2020,33(23):58.[doi:10.3969/j.issn.1006-1959.2020.02.016]
[2]袁 超.沙库巴曲缬沙坦联合比索洛尔治疗慢性心力衰竭的效果[J].医学信息,2020,33(19):135.[doi:10.3969/j.issn.1006-1959.2020.19.041]
　YUAN Chao.Effect of Sacubitril Valsartan Combined with Bisoprolol in the Treatment of Chronic Heart Failure[J].Journal of Medical Information,2020,33(23):135.[doi:10.3969/j.issn.1006-1959.2020.19.041]
[3]王晨青,李婧炜.沙库巴曲缬沙坦在心力衰竭中的应用现状[J].医学信息,2021,34(01):37.[doi:10.3969/j.issn.1006-1959.2021.01.011]
　WANG Chen-qing,LI Jing-wei.The Application Status of Sacubatril Valsartan in Heart Failure[J].Journal of Medical Information,2021,34(23):37.[doi:10.3969/j.issn.1006-1959.2021.01.011]
[4]韦怡春,易秋艳.沙库巴曲缬沙坦对心力衰竭患者抑郁的影响[J].医学信息,2021,34(23):29.[doi:10.3969/j.issn.1006-1959.2021.23.008]
　WEI Yi-chun,YI Qiu-yan.Effect of Sacubitril Valsartan on Depression in Patients with Heart Failure[J].Journal of Medical Information,2021,34(23):29.[doi:10.3969/j.issn.1006-1959.2021.23.008]
[5]熊鹏锋.沙库巴曲缬沙坦联合美托洛尔对青年扩张型心肌病患者心功能及预后的影响[J].医学信息,2022,35(20):80.[doi:10.3969/j.issn.1006-1959.2022.20.020]
　XIONG Peng-feng.Effect of Sacubitril Valsartan Combined with Metoprolol on Cardiac Function and Prognosis in Young Patients with Dilated Cardiomyopathy[J].Journal of Medical Information,2022,35(23):80.[doi:10.3969/j.issn.1006-1959.2022.20.020]
[6]葛文涛,程长生,胡成坤.强心贴联合沙库巴曲缬沙坦对慢性心力衰竭患者脑钠肽水平的影响[J].医学信息,2025,38(04):132.[doi:10.3969/j.issn.1006-1959.2025.04.024]
　GE Wentao,CHENG Changsheng,HU Chengkun.Effect of Qiangxin Paste Combined with Sacubitril Valsartan on Brain Natriuretic Peptide Level in Patients with Chronic Heart Failure[J].Journal of Medical Information,2025,38(23):132.[doi:10.3969/j.issn.1006-1959.2025.04.024]

更新日期/Last Update: 1900-01-01